<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783781</url>
  </required_header>
  <id_info>
    <org_study_id>15/E/01</org_study_id>
    <secondary_id>15.834</secondary_id>
    <secondary_id>1912114</secondary_id>
    <nct_id>NCT02783781</nct_id>
  </id_info>
  <brief_title>Contribution of Preoperative Biological Data in Risk Assessment in Cardiac Surgery in Addition to the EuroSCORE (EuroSCOREbio)</brief_title>
  <acronym>EuroSCOREbio</acronym>
  <official_title>Contribution of Preoperative Biological Data in Risk Assessment in Cardiac Surgery in Addition to the EuroSCORE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Center of Martinique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris, FRANCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Bordeaux, FRANCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Toulouse, FRANCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Clermont-Ferrand, FRANCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de La Réunion, FRANCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire d’Angers, FRANCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Dijon, FRANCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Center of Martinique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In cardiac surgery, the assessment of operative risk and quality of care is a major challenge
      for both patient, and surgical team. It is also important for health care decisionmakers to
      have predictive tools to compare alternative technics such as conventional cardiac surgery
      and interventional cardiology. Since 1998, the European System for Cardiac Operative Risk
      Evaluation (EuroSCORE), updated in 2012 (EuroSCORE II) is the most universally used system in
      this purpose. Its success is the result of a good balance between predictive capability and
      simplicity. It consists almost exclusively of clinical variables.

      However, the objectivity and the predictive ability of some of those clinical items remain
      controversial, particularly those addressing severity of illness for high-risk patients. For
      instance, the degree of priority is submitted to the subjective assessment by the surgical
      team at the time of surgery. Objective data describing the severity of patients arriving in
      the operating room are still missing.

      Many biomarkers are relevant in qualifying severity of syndromes: shock (PH, lactates, LDH),
      heart disease (N-terminal pro b-type natriuretic peptide (NTproBNP), troponin T and I),
      respiratory disorder (blood gaz analysis), liver insufficiency (TP, factor V), renal
      impairment (serum creatinine, creatinine clearance), inflammatory condition (fibrinogen,
      CRP), or the underlying medical condition such as diabetes (HbA1c, microalbuminuria) and
      nutritional status (albumin).

      In ICU, many scores use biological data to measure, on daily basis, the severity of the
      patient status. Their routine use is simplified by applications available on smartphones.
      They are drawn into hospital information systems.

      In cardiac surgery, some studies seem to demonstrate the measurement of some preoperative
      biological variables (eg NT Pro-BNP ...) in risk prediction. In terms of diabetes, HbA1c is
      of particular interest because it detects underlying diabetes if unknown (emergent situation)
      or reflects its poor control before surgery. This criterion could be more reliable than the
      simple information of patient treated by insulin (EuroSCORE II criterion).

      Finally, the reinforcement of existing scores with biological variables is recommended by the
      group of recommendations in prognostic research strategy (PROGRESS 2014), rather than
      creating new scores ex nihilo.

      The hypothesis is that adding biological data collected at the time of arrival of the patient
      in the operating room would better qualify the patients' severity condition and therefore
      increase the risk prediction of early mortality and severe morbidity after cardiac surgery.
      The purpose of this study is to test this hypothesis and especially test whether the
      biological data would increase the EuroSCORE II performance, by improving the prediction for
      high-risk patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective: To improve the EuroSCORE II predictive power on the 90-day mortality and/or
      severe hospital morbidity, incorporating immediate preoperative biological data.

      Secondary objectives:

        1. Analyze EuroSCORE II calibration by risk group (external validation).

        2. Studying the improvement of the EuroSCORE II-bio predictive power by risk class,
           especially high risk.

        3. Refine selection and definition of discriminating criteria for diabetics for predicting
           surgical risk in cardiac surgery (the HbA1c value, the existence of microalbuminuria,
           the nature of treatment etc.).

        4. Compare the risk profiles of operated patients in the French Overseas Departments to
           those from different sites of Western Europe.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of mortality at 90 days and/or occurence of severe morbidity during hospitalization.</measure>
    <time_frame>120 days</time_frame>
    <description>1- Mortality criterion 90-day mortality. In addition, the date of death from the surgery date and the release date from the hospital will clarify the subcategories (30-day mortality and hospital mortality).
2- Severe post operative morbidity Criteria
At least one of the following criteria:
i. Intensive care hospital stay&gt; 8 days ii. Total post operative hospital stay&gt; 21 days (full stay including intensive care) iii. Postoperative ventilation time&gt; 72 H and/or need for tracheotomy iv. Need for a &quot;neo-dialysis&quot; in postoperative v. Need for cardiac reoperation after surgery vi. Postoperative mediastinal infection vii. Permanent stroke post operatively. viii. Need for intra-aortic balloon pump or circulatory support for acute cardiopulmonary failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation criteria of risk profiles of population (French Overseas Department /Western Europe).</measure>
    <time_frame>120 days</time_frame>
    <description>The risk profile categories distribution in the EuroSCORE II grid, in the two subgroups (patients from French Overseas Department sites and patients of European sites).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">9500</enrollment>
  <condition>Patients Requiring Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Cardiac surgery</arm_group_label>
    <description>All patients (planned and urgent) needed cardiac surgery, and agreed to participate</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac surgery (extracorporeal circulation; beating heart)</intervention_name>
    <description>Patient's usual care as part of cardiac surgery, analysis of biological data collected at the time of arrival of the patient in the operating room.
Blood sample collection Urine sample collection</description>
    <arm_group_label>Cardiac surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients needed cardiac surgery during 1 year at the different sites (in France (8
        sites), and in two French Overseas Departments (2 sites))
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient &gt; 18 years old at the time of inclusion

          -  All patients operated on extracorporeal circulation or beating heart

          -  Patient affiliated to a social security scheme

          -  Patient having been informed of the research objectives

          -  Patient not objecting to participate in research

        Exclusion Criteria:

          -  Patient receiving heart transplant

          -  Patient &lt; 18 years old

          -  Patient refusing to participate in the study

          -  Pregnant women

          -  Protected adult (person under guardianship and trusteeship) or deprived of liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François ROQUES, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Martinique</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François ROQUES, MD, PhD</last_name>
    <email>françois.roques@chu-martinique.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Martinique</name>
      <address>
        <city>Fort-de-France</city>
        <state>Martinique</state>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann MOPSUS</last_name>
      <phone>+596 (0) 596 55 35 84</phone>
      <email>yann.mopsus@chu-martinique.fr</email>
    </contact>
    <investigator>
      <last_name>François ROQUES, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Louis DE BRUX, MD, PhD</last_name>
      <email>JlDebrux@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Louis DE BRUX, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louis LABROUSSE, MD, PhD</last_name>
      <email>louis.labrousse@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Louis LABROUSSE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel CAMILLERI, MD, PhD</last_name>
      <email>lcamilleri@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel CAMILLERI, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BOUCHOT, MD, PhD</last_name>
      <email>olivier.bouchot@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier BOUCHOT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre LE GUYADER, MD</last_name>
      <email>alexandre.LeGuyader@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandre LE GUYADER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal LEPRINCE, MD, PhD</last_name>
      <email>pascal.leprince@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal LEPRINCE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie PROVENCHERE-FRUTHIOT, MD</last_name>
      <email>sophie.provenchere@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie PROVENCHERE-FRUTHIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de La Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric BRAUNBERGER, MD, PhD</last_name>
      <email>eric.braunberger@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Eric BRAUNBERGER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Etienne GRUNENWALD, MD</last_name>
      <email>grunenwald.e@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Etienne GRUNENWALD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac surgery (extracorporeal circulation; beating heart)</keyword>
  <keyword>Biological data</keyword>
  <keyword>Preoperative biological variables</keyword>
  <keyword>EuroSCORE II</keyword>
  <keyword>Risk prediction</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

